Beta Pharma (300558.SZ) Reports Partner He Yuan Biotech's Novel Drug Ofumin Gains Market Approval

Stock News07-18

Beta Pharma Co., Ltd. (300558.SZ) announced its equity-method investee Wuhan He Yuan Biotechnology Co., Ltd. has secured regulatory approval for recombinant human serum albumin injection (rice-derived), marketed under the brand name Ofumin®. The newly approved therapeutic indication targets the treatment of hypoalbuminemia (≤30g/L) in liver cirrhosis patients.

This milestone marks a significant advancement for He Yuan Biotech's innovative biologic candidate developed through proprietary plant-based expression technology. The authorization enables commercial distribution of the albumin replacement therapy addressing a critical unmet medical need in hepatic disorders. As a strategic stakeholder, Beta Pharma stands to benefit from this product's market penetration through its equity participation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194645411?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-18 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194645411","market":"nz","top_or_hot":-1,"title":"Beta Pharma (300558.SZ) Reports Partner He Yuan Biotech's Novel Drug Ofumin Gains Market Approval","media":"Stock News","content":"<p>Beta Pharma Co., Ltd. (300558.SZ) announced its equity-method investee Wuhan He Yuan Biotechnology Co., Ltd. has secured regulatory approval for recombinant human serum albumin injection (rice-derived), marketed under the brand name Ofumin®. The newly approved therapeutic indication targets the treatment of hypoalbuminemia (≤30g/L) in liver cirrhosis patients.</p>\n<p>This milestone marks a significant advancement for He Yuan Biotech's innovative biologic candidate developed through proprietary plant-based expression technology. The authorization enables commercial distribution of the albumin replacement therapy addressing a critical unmet medical need in hepatic disorders. As a strategic stakeholder, Beta Pharma stands to benefit from this product's market penetration through its equity participation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beta Pharma (300558.SZ) Reports Partner He Yuan Biotech's Novel Drug Ofumin Gains Market Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeta Pharma (300558.SZ) Reports Partner He Yuan Biotech's Novel Drug Ofumin Gains Market Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-07-18 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beta Pharma Co., Ltd. (300558.SZ) announced its equity-method investee Wuhan He Yuan Biotechnology Co., Ltd. has secured regulatory approval for recombinant human serum albumin injection (rice-derived), marketed under the brand name Ofumin®. The newly approved therapeutic indication targets the treatment of hypoalbuminemia (≤30g/L) in liver cirrhosis patients.</p>\n<p>This milestone marks a significant advancement for He Yuan Biotech's innovative biologic candidate developed through proprietary plant-based expression technology. The authorization enables commercial distribution of the albumin replacement therapy addressing a critical unmet medical need in hepatic disorders. As a strategic stakeholder, Beta Pharma stands to benefit from this product's market penetration through its equity participation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1194645411","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194645411","pubTimestamp":1752838944,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beta Pharma Co., Ltd. (300558.SZ) announced its equity-method investee Wuhan He Yuan Biotechnology Co., Ltd. has secured regulatory approval for recombinant human serum albumin injection...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300558":"贝达药业","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"贝塔医药（300558.SZ）报告合作伙伴和元生物新药奥福明获得市场批准","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300558":1},"content_text":"Beta Pharma Co., Ltd. (300558.SZ) announced its equity-method investee Wuhan He Yuan Biotechnology Co., Ltd. has secured regulatory approval for recombinant human serum albumin injection (rice-derived), marketed under the brand name Ofumin®. The newly approved therapeutic indication targets the treatment of hypoalbuminemia (≤30g/L) in liver cirrhosis patients.\nThis milestone marks a significant advancement for He Yuan Biotech's innovative biologic candidate developed through proprietary plant-based expression technology. The authorization enables commercial distribution of the albumin replacement therapy addressing a critical unmet medical need in hepatic disorders. As a strategic stakeholder, Beta Pharma stands to benefit from this product's market penetration through its equity participation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194645411","isCrawlerRequest":true}